6.1(top 5%)
impact factor
321(top 50%)
papers
2.2K(top 50%)
citations
26(top 20%)
h-index
6.3(top 5%)
extended IF
368
all documents
2.8K
doc citations
38(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaBlood Cancer Discovery2020114
2Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic LeukemiaBlood Cancer Discovery202093
3Scalable Manufacturing of CAR T Cells for Cancer ImmunotherapyBlood Cancer Discovery202184
4Revealing the Impact of Structural Variants in Multiple MyelomaBlood Cancer Discovery202081
5Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapyBlood Cancer Discovery202171
6Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaBlood Cancer Discovery202270
7Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway ActivationBlood Cancer Discovery202164
8Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesBlood Cancer Discovery202162
9T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted TherapiesBlood Cancer Discovery202161
10Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsBlood Cancer Discovery202150
11COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersBlood Cancer Discovery202046
12Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesBlood Cancer Discovery202246
13Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapyBlood Cancer Discovery202144
14Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid LeukemiaBlood Cancer Discovery202043
15Bispecific Antibodies in Multiple Myeloma: Present and FutureBlood Cancer Discovery202143
16Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaBlood Cancer Discovery202141
17Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaBlood Cancer Discovery202140
18Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT PathwayBlood Cancer Discovery202040
19Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid LeukemiaBlood Cancer Discovery202238
20Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaBlood Cancer Discovery202238
21SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid LeukemiaBlood Cancer Discovery202137
22Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic TherapyBlood Cancer Discovery202137
23NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-ReactivityBlood Cancer Discovery202137
24A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid NeoplasmsBlood Cancer Discovery202136
25CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished ImmunityBlood Cancer Discovery202236
26Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote DifferentiationBlood Cancer Discovery202135
27Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II ExpressionBlood Cancer Discovery202235
28Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin LymphomaBlood Cancer Discovery202031
29Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed ImmunotherapiesBlood Cancer Discovery202231
30Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating FunctionsBlood Cancer Discovery202030
31Overcoming Acquired Epigenetic Resistance to BTK InhibitorsBlood Cancer Discovery202130
32Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaBlood Cancer Discovery202229
33Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in HealthcareBlood Cancer Discovery202127
34Hyperthermia Selectively Destabilizes Oncogenic Fusion ProteinsBlood Cancer Discovery202126
35Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDSBlood Cancer Discovery202125
36Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsBlood Cancer Discovery202225
37Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease ProgressionBlood Cancer Discovery202024
38Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal HematopoiesisBlood Cancer Discovery202124
39Perspectives on the Risk-Stratified Treatment of Multiple MyelomaBlood Cancer Discovery202224
40Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid LeukemiaBlood Cancer Discovery202123
41Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell TherapyBlood Cancer Discovery202223
42Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood CancersBlood Cancer Discovery202122
43Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin LymphomaBlood Cancer Discovery202122
44How to Provide the Needed Protection from COVID-19 to Patients with Hematologic MalignanciesBlood Cancer Discovery202122
45TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid LeukemiaBlood Cancer Discovery202122
46Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyBlood Cancer Discovery202322
47Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid LeukemiaBlood Cancer Discovery202021
48Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic IndicatorsBlood Cancer Discovery202121
49An Autochthonous Mouse Model ofMyd88- andBCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesBlood Cancer Discovery202121
50Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic LeukemiaBlood Cancer Discovery202021